Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
8328392
Reference Type
Journal Article
Title
Targeting the PI3K-AKT-mTOR singnaling network in cancer
Author(s)
Khan, KH; Yap, TA; Yan, L; Cunningham, D
Year
2013
Is Peer Reviewed?
Yes
Journal
Aizheng
ISSN:
1000-467X
Volume
32
Issue
5
Page Numbers
253-265
Language
English
DOI
10.5732/cjc.013.10057
Abstract
The phosphoinositide 3-kinase-AKT-mammalian target of rapamycin (PI3K-AKT-mTOR) pathway is a frequently hyperactivated pathway in cancer and is important for tumor cell growth and survival. The development of targeted therapies against mTOR, a vital substrate along this pathway, led to the approval of allosteric inhibitors, including everolimus and temsirolimus, for the treatment of breast, renal, and pancreatic cancers. However, the suboptimal duration of response in unselected patients remains an unresolved issue. Numerous novel therapies against critical nodes of this pathway are therefore being actively investigated in the clinic in multiple tumour types. In this review, we focus on the progress of these agents in clinical development along with their biological rationale, the need of predictive biomarkers and various combination strategies, which will be useful in counteracting the mechanisms of resistance to this class of drugs.
Keywords
Molecular therapeutics; PI3K-AKT-mTOR; PTEN; RTK; Signaling pathways
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity